Navigation Links
Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track. Garr will also present a business overview, including an update on the world's first FDA-approved stem cell injections in the cervical region, in its ongoing ALS cell therapy Phase I trial. He will also present an update on the recently FDA-approved advancement to Phase Ib dosing in depressed patients of its first-in-class NSI-189 small molecule drug, in its ongoing NSI-189/major depressive disorder (MDD) trial.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco, January 9-11. For more information, see: http://www.ebdgroup.com/bts/index.php. Biotech Showcase runs concurrently to the world's largest annual healthcare investor conference, and provides private and public life science companies the opportunity to present to an audience of investors and business development executives interested in innovative biotech companies.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosi
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
3. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
4. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
7. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
8. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
9. Neuralstem Completes $5.25 Million Financing
10. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
11. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
(Date:5/21/2013)... 21, 2013 Bed bugs have become so ... Cleaning Products, many turn to chemical-based pesticides for help to ... and environmental risks those solutions present, the company advised the ... Bully instead. , According to My Cleaning Products, chemical-based ... used to be. It shared that the pests have already ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Corporation announced today a,major new release of its ... greatly expanded analytical capabilities,while maintaining an emphasis on ... user with dozens of new image feature,calculations and ... new software also provides the user with much ...
... from PAREXEL,International Corporation (Nasdaq: PRXL ), a ... for,successful partnerships at the 17th Annual Partnerships with ... Las Vegas, Nevada. PAREXEL is,an Associate Sponsor of ... the following sessions, which address,the implementation of metrics ...
... announced that,researchers will present seven abstracts on the ... the American Association for,Cancer Research, exemplifying the company,s ... research has long been a core area of ... data from our increasingly large oncology portfolio at,this ...
Cached Biology Technology:Amnis Announces Release of Powerful New Image Data Analysis Software 2PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference 2PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference 3PAREXEL Experts to Offer Insights Into Outsourcing Best Practices at 17th Annual Partnerships with CROs Conference 4MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 2MedImmune Presents Data Highlighting its Progressive Oncology Portfolio at Annual Meeting of the American Association For Cancer Research 3
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
(Date:5/21/2013)... of Medicine will study gender differences in how the heart ... and how changes in fat metabolism play a role in ... the National Heart, Lung and Blood Institute. , When stressed, ... changes may play a major role in the development of ... E. Douglas Lewandowski, director of the UIC Center for Cardiovascular ...
(Date:5/21/2013)... American Chemical Society (ACS), the world,s largest scientific ... National Meeting & Exposition, September 8-12, 2013, in ... Indiana Convention Center and at area hotels. , ... that span science,s horizons from astronomy to ... and online journalists a rich assortment of spot ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
... mothers have known that feeding their kids milk builds strong ... at Intermountain Medical Center in Salt Lake City suggests that ... well and that inadequate levels of the vitamin may ... death, even among people who,ve never had heart disease. ...
... 13 2003 / b3c newswire / - TET Systems ... in controlled gene expression, today announced that TET Systems and ... Hagedorn Research Institute (HRI), a research institute within Novo Nordisk ... research activities. , TET Systems was founded by Prof. ...
... HUNTSVILLE Poor Texas. First it ... The invasion of this new species ... the hills, said Jerry Cook, an entomologist at Sam Houston State University., ... fast and furious spread of the rapacious ant, which is named after ...
Cached Biology News:New study links vitamin D deficiency to cardiovascular disease and death 2New study links vitamin D deficiency to cardiovascular disease and death 3TET Systems and Novo Nordisk sign license agreement 2Rapacious Rasberry ants march north 2
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... 18 amino acid synthetic peptide whose sequence corresponds to residues 1-18 ... (amino to carboxy terminus): M(1) - A - S - A ... S - P - R - D - A - A ... be used for neutralization and control experiments with the polyclonal antibody ...
Rabbit polyclonal antibody to Glutathione-S-Transferase (GST)...
... CHEMICON's In Vitro Osteogenesis Assay Kit contains ... to a mature osteoblastic lineage, as determined ... kit provides all the necessary reagents and ... standard plate reader. This product is useful ...
Biology Products: